Keros Therapeutics Inc (KROS) Stock AnalysisKROSKeros Therapeutics Inc

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, elritercept (KER-065), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A. Its lead product candidate, rinvatercept, is being developed for the treatment of neuromuscular diseases. Elritercept is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Keros Therapeutics Inc is not a good buy right now due to its current price of $10.66 being significantly below analyst targets, with BofA at $17 and Wells Fargo at $18. The company has a high forward P/E of 48.78, indicating potential overvaluation, and the RSI is at 29.465, suggesting it is oversold. Additionally, the stock has seen a 42.50% decline year-to-date, reflecting ongoing market concerns. The main risk is the negative earnings trend, with EPS reported at -1.45, which raises questions about profitability and future growth.